OSTX Stock Forecast & Price Target

OS Therapies is showcasing a promising pipeline of product candidates targeting multiple indications for solid cancers with a primary focus on metastatic osteosarcoma, complemented by potential applications in other rare and aggressive cancers. The company's lead drug, OST-HER2, is garnering significant attention with its potential for accelerated regulatory pathways in both the US and Europe and a PRV monetization, which could provide a significant capital infusion. The recent coordination with regulatory authorities for the design of a global confirmatory Phase 3 trial and upcoming key milestones in 2026 further add to the positive outlook for the stock.

OS Therapies is facing key upcoming catalysts in their mission to address the need for new treatments in cancers of the bone, including FDA Pre-BLA Type B meeting, MHRA regulatory alignment, and potential BLA submission. However, due to a lack of recent clinical readouts, investors will focus on the regulatory feedback and the potential for non-dilutive financing opportunities through regulatory designations and Priority Review Vouchers. With the company facing several years of development and potential regulatory hurdles, financial analysts may have a negative outlook on the stock.